{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:50:12Z","timestamp":1779889812494,"version":"3.53.1"},"reference-count":56,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2022,12,2]]},"DOI":"10.1080\/14740338.2022.2160447","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T03:41:15Z","timestamp":1671248475000},"page":"1445-1451","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":28,"title":["Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4658-7391","authenticated-orcid":false,"given":"Angelo","family":"Ruggiero","sequence":"first","affiliation":[{"name":"University of Naples Federico II","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7201-9163","authenticated-orcid":false,"given":"Elisa","family":"Camela","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-1874","authenticated-orcid":false,"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Napoli, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2036674"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15214"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S328460"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00578-0"},{"issue":"10230","key":"e_1_3_6_9_1","first-page":"1115","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"DISCOVER-1 Study Group","unstructured":"DISCOVER-1 Study Group, Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1115\u20131125.","journal-title":"Lancet"},{"issue":"10230","key":"e_1_3_6_10_1","first-page":"1126","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"DISCOVER-2 Study Group","unstructured":"DISCOVER-2 Study Group, Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1126\u20131136.","journal-title":"Lancet"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18167"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-021-02200-7"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1800577"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13964"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16128"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v101.283"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.025"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14673"},{"key":"e_1_3_6_22_1","first-page":"205","article-title":"Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study","volume":"12","author":"Megna M","unstructured":"Megna M, Potestio L, Fabbrocini G, et al. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl). 2022 Jul 14;12:205\u2013212.","journal-title":"Psoriasis (Auckl)"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00556-2"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15524"},{"key":"e_1_3_6_25_1","first-page":"e15941","article-title":"Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study","volume":"14","author":"Ruggiero A","year":"2022","unstructured":"Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;14:e15941.","journal-title":"Dermatol Ther"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2089020"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13932"},{"key":"e_1_3_6_28_1","unstructured":"Tildrakizumab (ILUMYA) Prescribing information. cited 2022 Jul 23 Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761067s000lbl.pdf"},{"key":"e_1_3_6_29_1","first-page":"276","volume-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","author":"Reich K","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. 2017. Vol. 390. England: Lancet (London; p. 276\u2013288."},{"key":"e_1_3_6_30_1","first-page":"127","article-title":"Bimekizumab for the treatment of psoriasis: a review of the current knowledge","volume":"12","author":"Ruggiero A","unstructured":"Ruggiero A, Potestio L, Camela E, et al. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis (Auckl). 2022 Jun 8;12:127\u2013137.","journal-title":"Psoriasis (Auckl)"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.702776"},{"key":"e_1_3_6_32_1","unstructured":"Tildrakizumab summary of product characteristic. cited 2022 Jul 23. Ilumetri INN-tildrakizumab (europa.eu)"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S227880"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319865658"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13001"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219014"},{"key":"e_1_3_6_37_1","first-page":"35(8):e526","article-title":"Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1","author":"Cantrell W","year":"2021","unstructured":"Cantrell W, Lee P, Mendelsohn AM, et al. Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e526\u2013e528.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19866"},{"key":"e_1_3_6_40_1","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.18368","article-title":"Efficacy, safety and patient\u2019s satisfaction for treatment of genital psoriasis with tildrakizumab: a case series and review of literature","volume":"36","author":"Licata G","year":"2022","unstructured":"Licata G, Danzuso GCL, Fiorella C, et al. Efficacy, safety and patient\u2019s satisfaction for treatment of genital psoriasis with tildrakizumab: a case series and review of literature. J. Eur. Acad. Dermatol. 2022 Nov;36(11):e916-e918.","journal-title":"J. Eur. Acad. Dermatol"},{"key":"e_1_3_6_41_1","doi-asserted-by":"crossref","first-page":"e15030","DOI":"10.1111\/dth.15030","article-title":"Tildrakizumab: a new therapeutic option for erythrodermic psoriasis?","volume":"34","author":"Megna M","year":"2021","unstructured":"Megna M, Potestio L, Fabbrocini G, et al. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021 Sep;34(5):e15030.","journal-title":"Dermatol Ther"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13642"},{"key":"e_1_3_6_43_1","article-title":"Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis","volume":"7","author":"Galluzzo M","year":"2022","unstructured":"Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022 May 7;11(9):2631.","journal-title":"J Clin Med"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000519924"},{"key":"e_1_3_6_45_1","first-page":"e15488","article-title":"Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study","volume":"35","author":"Caldarola G","year":"2022","unstructured":"Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022;35:e15488.","journal-title":"Dermatol Ther"},{"key":"e_1_3_6_46_1","article-title":"Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting","volume":"21","author":"Burlando M","year":"2021","unstructured":"Burlando M, Castelli R, Cozzani E, et al. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021 May 21;10:2021-2-6.","journal-title":"Drugs Context"},{"key":"e_1_3_6_47_1","first-page":"Sep;33(6):2813","article-title":"Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study","author":"Megna M","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022 Sep;33(6):2813\u20132820.","journal-title":"J Dermatolog Treat"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14979"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15228"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.1988566"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17918"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.59"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143394"},{"key":"e_1_3_6_55_1","first-page":"1","article-title":"New frontiers in personalized medicine in psoriasis","volume":"16","author":"Camela E","year":"2022","unstructured":"Camela E, Potestio L, Fabbrocini G, et al. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;16:1\u20133.","journal-title":"Expert Opin Biol Ther"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14433"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101482"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13238"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2022.2160447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:04:20Z","timestamp":1772744660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2022.2160447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,2]]}},"alternative-id":["10.1080\/14740338.2022.2160447"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2022.2160447","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}